<DOC>
	<DOCNO>NCT02336503</DOCNO>
	<brief_summary>To assess safety efficacy 3 dose BBI-4000 vehicle ( 4 treatment arm ) , apply day 4 week , treatment axillary hyperhidrosis .</brief_summary>
	<brief_title>A Safety Efficacy Study BBI-4000 Subjects With Axillary Hyperhidrosis</brief_title>
	<detailed_description>This Multicenter , Randomized , Double Blind , Vehicle-Controlled Study Evaluate Safety Efficacy 3 concentration Topically Applied BBI-4000 Subjects Axillary Hyperhidrosis . Participating subject apply BBI-4000 day 4 week axillae . The 4 week treatment period follow 2 week follow-up period . Safety assess collection vital sign , adverse event , local skin response , hematology serum chemistry laboratory test ECGs . Efficacy assess use Hyperhidrosis Disease Severity Scale ( patient report outcome ) gravimetrically measure sweat production . PK blood sample take study subject select center .</detailed_description>
	<mesh_term>Hyperhidrosis</mesh_term>
	<criteria>Primary axillary hyperhidrosis least 6 month 's duration Hyperhidrosis disease severity score 3 4 baseline Gravimetric test baseline indicate least 50 mg sweat production rest axilla , 5 minute ( room temperature ) Willing refrain use antiperspirant agent duration study . Females childbearing potential must agree use medically acceptable method contraception participate study . Any skin subcutaneous tissue condition axilla near axillary area , hyperhidrosis . Prior use prohibit medication ( ) procedure ( ) within specify timeframe , include : 1 . Botulinum toxin axillary area within 1 year baseline visit . 2 . Axillary iontophoresis within 12 week baseline visit . 3 . Axillary thermolysis , sympathectomy surgical procedure axillary area time past . Use systemic and/or topical anticholinergic treatment within 30 day baseline visit . Subjects hyperhidrosis symptom initiate exacerbated menopause . Subjects history diabetes mellitus , renal impairment , hepatic impairment , thyroid disease , malignancy , glaucoma , intestinal obstructive motility disease , obstructive uropathy , myasthenia gravis , benign prostatic hyperplasia ( BPH ) , neurological condition , psychiatric condition , Sj√∂gren 's syndrome , Sicca syndrome , cardiac abnormality may alter normal sweat production may exacerbate use anticholinergic . Subjects know hypersensitivity glycopyrrolate , anticholinergic , component topical formulation . Pregnant lactating woman . Use investigational drug within 30 day prior baseline visit . Prior treatment study drug previous trial . Any major illness within 30 day screen examination . Any condition laboratory abnormality , judgment investigator , would put subject unacceptable risk participation study may interfere assessment include study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>